<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Br J Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Br. J. Pharmacol</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1476-5381</journal-id>
<journal-id journal-id-type="publisher-id">BPH</journal-id>
<journal-title-group>
<journal-title>British Journal of Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0007-1188</issn>
<issn pub-type="epub">1476-5381</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28378414</article-id>
<article-id pub-id-type="pmc">6016632</article-id>
<article-id pub-id-type="doi">10.1111/bph.13757</article-id>
<article-id pub-id-type="publisher-id">BPH13757</article-id>
<article-id pub-id-type="other">2016-BJP-1143-RCT-G.R1</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Review Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Themed Section: Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Oxytocin and opioid addiction revisited: old drug, new applications</article-title>
<alt-title alt-title-type="right-running-head">Oxytocin and opioid addiction revisited</alt-title>
<alt-title alt-title-type="left-running-head">P Zanos et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="bph13757-cr-0001">
<name>
<surname>Zanos</surname>
<given-names>Panos</given-names>
</name>
<xref ref-type="aff" rid="bph13757-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="bph13757-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13757-cr-0002">
<name>
<surname>Georgiou</surname>
<given-names>Polymnia</given-names>
</name>
<xref ref-type="aff" rid="bph13757-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="bph13757-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13757-cr-0003">
<name>
<surname>Weber</surname>
<given-names>Carol</given-names>
</name>
<xref ref-type="aff" rid="bph13757-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13757-cr-0004">
<name>
<surname>Robinson</surname>
<given-names>Fiona</given-names>
</name>
<xref ref-type="aff" rid="bph13757-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13757-cr-0005">
<name>
<surname>Kouimtsidis</surname>
<given-names>Christos</given-names>
</name>
<xref ref-type="aff" rid="bph13757-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13757-cr-0006">
<name>
<surname>Niforooshan</surname>
<given-names>Ramin</given-names>
</name>
<xref ref-type="aff" rid="bph13757-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="bph13757-cr-0007">
<name>
<surname>Bailey</surname>
<given-names>Alexis</given-names>
</name>
<address>
<email>abailey@sgul.ac.uk</email>
</address>
<xref ref-type="aff" rid="bph13757-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="bph13757-aff-0003">
<sup>3</sup>
</xref>
</contrib>
</contrib-group>
<aff id="bph13757-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">School of Biosciences and Medicine, Faculty of Health and Medical Sciences</named-content>
<institution>University of Surrey</institution>
<named-content content-type="city">Guildford</named-content>
<named-content content-type="country-part">Surrey</named-content>
<country country="GB">UK</country>
</aff>
<aff id="bph13757-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>University of Maryland School of Medicine</institution>
<named-content content-type="city">Baltimore</named-content>
<named-content content-type="country-part">MD</named-content>
<country country="US">USA</country>
</aff>
<aff id="bph13757-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Institute of Medical and Biomedical Education</named-content>
<institution>St George's University of London</institution>
<named-content content-type="city">London</named-content>
<country country="GB">UK</country>
</aff>
<aff content-type="private-address" id="bph13757-aff-0004">
<label><sup>4</sup></label>
<institution>Surrey and Borders Partnership NHS Foundation Trust</institution>
<named-content content-type="city">Chertsey</named-content>
<named-content content-type="country-part">Surrey</named-content>
<country country="GB">UK</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label>
Correspondence<break></break>
Alexis Bailey, Institute of Medical and Biomedical Education, St George's University of London, London SW17 0RE, UK.<break></break>
E‐mail: <email>abailey@sgul.ac.uk</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>06</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2018</year>
</pub-date>
<volume>175</volume>
<issue>14</issue>
<issue-id pub-id-type="doi">10.1111/bph.v175.14</issue-id>
<issue-title content-type="special-issue-title">Themed Section: Emerging Areas of Opioid Pharmacology. Guest Editors: Eamonn Kelly, Graeme Henderson and Chris P Bailey</issue-title>
<fpage>2809</fpage>
<lpage>2824</lpage>
<history>
<date date-type="received">
<day>11</day>
<month>12</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>01</day>
<month>2</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>2</month>
<year>2017</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 The British Pharmacological Society <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2017 The British Pharmacological Society</copyright-statement>
</permissions>
<self-uri content-type="pdf" xlink:href="file:BPH-175-2809.pdf" xlink:type="simple"></self-uri>
<abstract>
<sec id="bph13757-sec-0100">
<p>Opioid addiction has devastating health and socio‐economic consequences, and current pharmacotherapy is limited and often accompanied by side effects, thus novel treatment is warranted. Traditionally, the neurohypophyseal peptide oxytocin (OT) is known for its effects on mediating reward, social affiliation and bonding, stress and learning and memory. There is now strong evidence that OT is a possible candidate for the treatment of drug addiction and depression‐addiction co‐morbidities. This review summarizes and critically discusses the preclinical evidence surrounding the consequences of pharmacological manipulation of the oxytocinergic system on opioid addiction‐related processes, as well as the effects of opioids on the OT system at different stages of the addiction cycle. The mechanisms underlying the effects of OT on opioid addiction, including OT' interaction with the monoaminergic, glutamatergic, opioidergic systems and its effect on the amygdala, the hypothalamic–pituitary–adrenal axis and on memory consolidation of traumatic memories, are also reviewed. We also review clinical evidence on the effects of intranasal OT administration on opioid‐dependent individuals and discuss the therapeutic potential along with the limitations that accompany OT‐based pharmacotherapies. Review of these studies clearly indicates that the OT system is profoundly affected by opioid use and abstinence and points towards the OT system as an important target for developing pharmacotherapies for the treatment of opioid addiction and co‐existing affective disorders, thereby preventing relapse. Therefore, there is a clear need for clinical studies assessing the efficacy of OT‐based pharmacotherapies in opioid addiction.</p>
</sec>
<sec id="bph13757-sec-0101">
<title>Linked Articles</title>
<p>This article is part of a themed section on Emerging Areas of Opioid Pharmacology. To view the other articles in this section visit <ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.14/issuetoc">http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.14/issuetoc</ext-link>
</p>
</sec>
</abstract>
<counts>
<fig-count count="0"></fig-count>
<table-count count="2"></table-count>
<page-count count="16"></page-count>
<word-count count="5577"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>bph13757</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>July 2018</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.4.1.1 mode:remove_FC converted:25.06.2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="bph13757-cit-0001" publication-type="journal">
<string-name>
<surname>Zanos</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Georgiou</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Weber</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>F.</given-names>
</string-name>, <string-name>
<surname>Kouimtsidis</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Niforooshan</surname>
<given-names>R.</given-names>
</string-name>, and <string-name>
<surname>Bailey</surname>
<given-names>A.</given-names>
</string-name> (<year>2018</year>) <article-title>Oxytocin and opioid addiction revisited: old drug, new applications</article-title>, <source xml:lang="en"/>British Journal of Pharmacology, <volume>175</volume>: <fpage>2809</fpage>–<lpage>2824</lpage>, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/bph.13757">https://doi.org/10.1111/bph.13757</ext-link>.</mixed-citation>
</p>
</notes>
</front>
</article>
</pmc-articleset>